ALX Oncology to Present Updated Results from Phase 2 ASPEN-06 Clinical Trial of Evorpacept in Patients with HER2-Positive Gastric Cancer in Oral Presentation at 2025 ASCO Gastrointestinal Cancers Symposium
ALXO 12.18.2024
Drug:ALX148-Unknown evorpacept
Diseases:HER2-positive gastric/gastroesophageal junction cancer
Date of Upcoming Event:2025-01-23
Name of Upcoming Event:2025 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium
About Gravity Analytica
Recent News
- 01.23.2025 - ASPEN-06 ASCO GI Data Review
- 01.23.2025 - ALX Oncology Presents Positive Updated Data from ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Generates Strong Response and Durable Clinical Benefit in Patients with HER2-Positive Gastric Cancer
- 01.23.2025 - Chris Takimoto, M.D., Ph.D., F.A.C.P.
Recent Filings
SOUTH SAN FRANCISCO, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients’ lives, today announced that the updated results from its Phase 2 ASPEN-06 clinical trial have been accepted for oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, which will be held in San Francisco from January 23 - 25, 2025.
ASPEN-06 is a randomized, multi-center, international trial (NCT05002127)evaluating evorpacept, ALX Oncology’s investigational CD47-blocking therapeutic that uniquely combines a high-affinity CD47-binding domain with an inactivated proprietary Fc domain, in combination with trastuzumab, CYRAMZA® (ramucirumab) and paclitaxel (collectively, TRP) against TRP alone for the treatment of patients with HER2-positive gastric/gastroesophageal junction cancer, where all patients had received an anti-HER2 agent in prior lines of therapy.
The updated results from the ASPEN-06 study will be detailed in the following oral presentation:
Title:Final analysis of the randomized phase 2 part of the ASPEN-06 study: A phase 2/3 study of evorpacept (ALX148), a CD47 myeloid checkpoint inhibitor, in patients with HER2-overexpressing gastric/gastroesophageal cancer (GC)Abstract Number:332Presenter:Kohei Shitara, MD, Director of the Department of Gastrointestinal Oncology, at National Cancer Center Hospital East, Kashiwa in JapanPresentation Date and Time:Thursday, January 23, 2025, from 9:15 a.m. – 10:00 a.m. PSTSession Information:Rapid Oral Abstract Session A: Cancers of the Esophagus and StomachLocation:Level 2 Ballroom
Copies of the presentations will be available on thePublicationssection of ALX Oncology’s website following presentation at the meeting.
About ALX OncologyALX Oncology (Nasdaq: ALXO) is a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients’ lives. ALX Oncology’s lead therapeutic candidate, evorpacept, has demonstrated potential to serve as a cornerstone therapy upon which the future of immuno-oncology can be built. Evorpacept is currently being evaluated across multiple ongoing clinical trials in a wide range of cancer indications. More information is available atwww.alxoncology.comand on LinkedIn @ALX Oncology.
Company Contact:Caitlyn Doherty, Manager, Corporate Communications, ALX Oncologycdoherty@alxoncology.com(650) 466-7125Media Contact:Audra Friis, Sam Brown, Inc.audrafriis@sambrown.com(917) 519-9577